Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial
- Citation:
- Am J Clin Oncol vol 35 (5) 418-423
- Year:
- 2012
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- N01 CA035431, U10 CA035269, CA-37404, U10 CA025224-30S2, CA-45450, CA-35195, U10 CA037404, U10 CA063849-16, U10 CA035195, CA-35103, CA-25224, U10 CA037404-21, U10 CA035272-26, U10 CA035272, U10 CA035269-28, U10 CA045450, U10 CA063849, U10 CA035431, UG1 CA189808, CA-35272, CA-35269, U10 CA025224, CA-63849, U10 CA035195-26, U10 CA035431-24, U10 CA035103, U10 CA045450-24
- Corr. Author:
- Authors:
- Steven R. Alberts Joel M. Reid Bruce W. Morlan Gist H. Farr John K. Camoriano David B. Johnson James R. Egner Thomas E. Seay George P. Kim
- Networks:
- Study
- NCCTG-N0041
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Article